{"jsonapi":{"version":"1.0"},"data":{"type":"recalls","id":"952b1e3dbfcc251d0c870d6744ce9f1aaa9451d4fb548d8d4932c826c0c214e0","attributes":{"feedName":"medwatch","feedSource":"medwatch","title":"Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib): Drug Safety Communication - Due to Rare but Severe Lung Inflammation","description":"FDA is warning that Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib) used to treat some patients with advanced breast cancers may cause rare but severe inflammation of the lungs.","link":"http://www.fda.gov/safety/medical-product-safety-information/ibrance-palbociclib-kisqali-ribociclib-and-verzenio-abemaciclib-drug-safety-communication-due-rare","publicationDate":"2019-09-13T16:00:00.000Z","state":"sent","affected":[],"allergens":[],"audience":["consumers","professionals"],"categories":["drugs"],"contaminants":[],"distribution":["AK","AL","AR","AZ","CA","CO","CT","DC","DE","FL","GA","HI","IA","ID","IL","IN","KS","KY","LA","MA","MD","ME","MI","MN","MO","MS","MT","NC","ND","NE","NH","NJ","NM","NV","NY","OH","OK","OR","PA","RI","SC","SD","TN","TX","UT","VA","VT","WA","WI","WV","WY"],"risk":"possible","token":"5da0a8394352a900013e5917"}}}